Antithrombotic Treatments in Patients with Chronic Coronary Artery Disease or Peripheral Artery Disease: A Systematic Review of Randomised Controlled Trials.
Rupert M BauersachsOlivia WuJean-Baptiste BriereKevin BowrinKatarzyna BorkowskaAnna JakubowskaVanessa TaiebMondher ToumiMaria HuelsebeckPublished in: Cardiovascular therapeutics (2020)
There is limited and heterogeneous evidence on the prevention of atherothrombotic events in patients with chronic CAD or PAD. Clopidogrel alone and clopidogrel plus ASA did not demonstrate superiority over ASA alone. A combination of rivaroxaban plus ASA may offer significant additional benefit in reducing cardiovascular outcomes, yet it may increase the risk of bleeding, compared to ASA alone.
Keyphrases
- coronary artery disease
- percutaneous coronary intervention
- atrial fibrillation
- peripheral artery disease
- acute coronary syndrome
- antiplatelet therapy
- coronary artery bypass grafting
- venous thromboembolism
- cardiovascular events
- pulmonary embolism
- heart failure
- type diabetes
- cardiovascular disease
- aortic valve
- ejection fraction
- aortic stenosis